BUSINESS● LOW2h ago · Oct 1, 2026, 6:04 PM
Spyre draws new Overweight at J.P. Morgan on IBD potential
Seeking Alpha Tech · global
J.P. Morgan has issued a new "Overweight" rating for Spyre, citing its potential in Inflammatory Bowel Disease (IBD). This analyst rating provides an investment perspective for the company.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Business
BUSINESSnowMunicipal Securities Underwriters Pay a Total of $325,000 in FinesSECBUSINESSnowSEC CHAIRMAN ARTHUR LEVITT, IOWA OFFICIALS TO HOLD INVESTORS’ TOWN MEETING IN DES MOINESSECBUSINESS18m agoVS Media Holdings reports 1H resultsSeeking Alpha TechBUSINESS21m agoEarnings Snapshot: Nike Q1 China, Direct drag revenue 4% lower; FY27 guidance softSeeking Alpha Tech